Epigenetic biomarkers in urothelial bladder cancer

Reference

• Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J. Clin.51(1), 15–36 (2001).
   PubMed Web of Science ®Google Scholar
• Messing EM. Urothelial tumors of the bladder. In: Campbell-Walsh Urology (Volume 3). Wein AJ (Ed.). Saunders Publishers, PA, USA, 2407–2446 (2006).
   Google Scholar
• Czerniak B, Herz F, Wersto RP, Koss LG. Asymmetric distribution of oncogene products at mitosis. Proc. Natl Acad. Sci. USA89(11), 4860–4863 (1992).
   PubMedGoogle Scholar
• Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med.329(18), 1318–1327 (1993).
   PubMed Web of Science ®Google Scholar
• Al-Sukhun S, Hussain M. Molecular biology of transitional cell carcinoma. Crit. Rev. Oncol. Hematol.47(2), 181–193 (2003).
   PubMedGoogle Scholar
• Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol. Res.26(4), 223–233 (1998).
   PubMedGoogle Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.3(6), 415–428 (2002).
   PubMed Web of Science ®Google Scholar
• Jones PA, Laird PW. Cancer epigenetics comes of age. Nat. Genet.21(2), 163–167 (1999).
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med.349(21), 2042–2054 (2003).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Knudson AG. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer1(2), 157–162 (2001).
   PubMed Web of Science ®Google Scholar
• Homma N, Tamura G, Honda T et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci.97(1), 51–56 (2006).
   PubMed Web of Science ®Google Scholar
• Tozawa T, Tamura G, Honda T et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci.95(9), 736–740 (2004).
   PubMed Web of Science ®Google Scholar
• Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci.99(4), 646–652 (2008).
   PubMedGoogle Scholar
• Uematsu F, Takahashi M, Yoshida M, Igarashi M, Nakae D. Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Sci.97(7), 611–617 (2006).
   PubMed Web of Science ®Google Scholar
• Saito Y, Liang G, Egger G et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell9(6), 435–443 (2006).
   PubMed Web of Science ®Google Scholar
• Lujambio A, Ropero S, Ballestar E et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res.67(4), 1424–1429 (2007).
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim EJ, Jeong P et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res.65(20), 9347–9354 (2005).
   PubMed Web of Science ®Google Scholar
• Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res.61(24), 8659–8663 (2001).
   PubMed Web of Science ®Google Scholar
• Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res.60(15), 4021–4025 (2000).
   PubMed Web of Science ®Google Scholar
• Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J. Urol.180(3), 1141–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Chan MW, Chan LW, Tang NL et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res.8(2), 464–470 (2002).
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Weisenberger DJ, Cheng JC et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res.10(22), 7457–7465 (2004).
   PubMed Web of Science ®Google Scholar
• Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst.98(14), 996–1004 (2006).
   PubMedGoogle Scholar
• Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene25(13), 1984–1988 (2006).
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature301(5895), 89–92 (1983).
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res.48(5), 1159–1161 (1988).
   PubMed Web of Science ®Google Scholar
• Rideout WM 3rd, Coetzee GA, Olumi AF, Jones PA. 5-methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science249(4974), 1288–1290 (1990).
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature429(6990), 457–463 (2004).
   PubMed Web of Science ®Google Scholar
• Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res.54(18), 4855–4878 (1994).
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, Tang M, Denissenko MF. Mutation hotspots and DNA methylation. Curr. Top. Microbiol. Immunol.249, 1–19 (2000).
   PubMed Web of Science ®Google Scholar
• Esteller M, Fraga MF, Guo M et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet.10(26), 3001–3007 (2001).
   PubMed Web of Science ®Google Scholar
• Grady WM, Willis J, Guilford PJ et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet.26(1), 16–17 (2000).
   PubMed Web of Science ®Google Scholar
• Burbee DG, Forgacs E, Zochbauer-Muller S et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl Cancer Inst.93(9), 691–699 (2001).
   PubMed Web of Science ®Google Scholar
• Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet.25(3), 315–319 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Gabrielson E, Chen W et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet.31(2), 141–149 (2002).
   PubMed Web of Science ®Google Scholar
• Yamashita K, Upadhyay S, Osada M et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell2(6), 485–495 (2002).
   PubMed Web of Science ®Google Scholar
• Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer5(3), 223–231 (2005).
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Bajorin DF, Reuter VE et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol.13(6), 1384–1390 (1995).
   PubMed Web of Science ®Google Scholar
• Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur. Urol.38(6), 691–699; discussion 700 (2000).
   PubMed Web of Science ®Google Scholar
• Sengelov L, Horn T, Steven K. p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J. Cancer Res. Clin. Oncol.123(10), 565–570 (1997).
   PubMedGoogle Scholar
• Catto JW, Azzouzi AR, Rehman I et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol.23(13), 2903–2910 (2005).
   PubMed Web of Science ®Google Scholar
• Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin. Cancer Res.10(6), 1887–1893 (2004).
   PubMed Web of Science ®Google Scholar
• Ahrendt SA, Chow JT, Xu LH et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst.91(4), 332–339 (1999).
   PubMed Web of Science ®Google Scholar
• Christoph F, Weikert S, Kempkensteffen C et al. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int. J. Cancer119(6), 1396–1402 (2006).
   PubMedGoogle Scholar
• Dominguez G, Carballido J, Silva J et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res.8(4), 980–985 (2002).
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Chandrasoma S, Siegmund KD et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer,41(17), 2769–2778 (2005).
   PubMed Web of Science ®Google Scholar
• Valenzuela MT, Galisteo R, Zuluaga A et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur. Urol.42(6), 622–628; discussion 628–630 (2002).
   PubMed Web of Science ®Google Scholar
• Bibikova M, Lin Z, Zhou L et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res.16(3), 383–393 (2006).
   PubMed Web of Science ®Google Scholar
• Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer3(4), 253–266 (2003).
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA95(20), 11891–11896 (1998).
   PubMed Web of Science ®Google Scholar
• Goessl C, Krause H, Muller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res.60(21), 5941–5945 (2000).
   PubMed Web of Science ®Google Scholar
• Sanchez-Cespedes M, Esteller M, Wu L et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res.60(4), 892–895 (2000).
   PubMed Web of Science ®Google Scholar
• Habuchi T, Takahashi T, Kakinuma H et al. Hypermethylation at 9q32–33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene20(4), 531–537 (2001).
   PubMed Web of Science ®Google Scholar
• Tada Y, Wada M, Taguchi K et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res.62(14), 4048–4053 (2002).
   PubMed Web of Science ®Google Scholar
• Yates DR, Rehman I, Abbod MF et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res.13(7), 2046–2053 (2007).
   PubMed Web of Science ®Google Scholar
• Aleman A, Adrien L, Lopez-Serra L et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br. J. Cancer98(2), 466–473 (2008).
   PubMed Web of Science ®Google Scholar
• Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am. J. Pathol.159(3), 831–835 (2001).
   PubMed Web of Science ®Google Scholar
• Chan MW, Chan LW, Tang NL et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int. J. Cancer104(5), 611–616 (2003).
   PubMed Web of Science ®Google Scholar
• Chang LL, Yeh WT, Yang SY, Wu WJ, Huang CH. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J. Urol.170(2 Pt 1), 595–600 (2003).
   PubMedGoogle Scholar
• Horikawa Y, Sugano K, Shigyo M et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J. Urol.169(4), 1541–1545 (2003).
   PubMedGoogle Scholar
• Lee MG, Kim HY, Byun DS et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res.61(18), 6688–6692 (2001).
   PubMedGoogle Scholar
• Ribeiro-Filho LA, Franks J, Sasaki M et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol. Carcinog.34(4), 187–198 (2002).
   PubMedGoogle Scholar
• Sathyanarayana UG, Maruyama R, Padar A et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res.64(4), 1425–1430 (2004).
   PubMed Web of Science ®Google Scholar
• Urakami S, Shiina H, Enokida H et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin. Cancer Res.12(7 Pt 1), 2109–2116 (2006).
   PubMed Web of Science ®Google Scholar
• Issa JP. The epigenetics of colorectal cancer. Ann. NY Acad. Sci.910, 140–153; discussion 153–145 (2000).
   PubMed Web of Science ®Google Scholar
• Issa JP. Epigenetic variation and human disease. J. Nutr.132(8 Suppl.), 2388S–2392S (2002).
   PubMed Web of Science ®Google Scholar
• So K, Tamura G, Honda T et al. Multiple tumor suppressor genes are increasingly methylated with age in non-neoplastic gastric epithelia. Cancer Sci.97(11), 1155–1158 (2006).
   PubMed Web of Science ®Google Scholar
• Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res.58(23), 5489–5494 (1998).
   PubMed Web of Science ®Google Scholar
• Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet.7(4), 536–540 (1994).
   PubMed Web of Science ®Google Scholar
• Shen L, Ahuja N, Shen Y et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl Cancer Inst.94(10), 755–761 (2002).
   PubMedGoogle Scholar
• Brooks JD, Weinstein M, Lin X et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev.7(6), 531–536 (1998).
   PubMed Web of Science ®Google Scholar
• Henrique R, Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur. Urol.46(5), 660–669; discussion 669 (2004).
   PubMed Web of Science ®Google Scholar
• Pu RT, Laitala LE, Clark DP. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol.50(5), 499–506 (2006).
   PubMed Web of Science ®Google Scholar
• Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol. Clin. North Am.30(4), 765–776 (2003).
   PubMedGoogle Scholar
• Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology66(6 Suppl. 1), 64–74 (2005).
   PubMed Web of Science ®Google Scholar
• Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology67(3 Suppl. 1), 25–33; discussion 33–24 (2006).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–465; discussion 475–477 (2006).
   PubMed Web of Science ®Google Scholar
• Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet.24(2), 132–138 (2000).
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N. Engl. J. Med.358(11), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res.61(8), 3225–3229 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf P, Hu YC, Doffek K, Sidransky D, Ahrendt SA. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res.61(22), 8113–8117 (2001).
   PubMedGoogle Scholar
• Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA91(24), 11733–11737 (1994).
   PubMed Web of Science ®Google Scholar
• Chen W, Cooper TK, Zahnow CA et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell6(4), 387–398 (2004).
   PubMed Web of Science ®Google Scholar
• Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell123(3), 437–448 (2005).
   PubMed Web of Science ®Google Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet.8(4), 286–298 (2007).
   PubMed Web of Science ®Google Scholar
• Ellinger J, El Kassem N, Heukamp LC et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol.179(1), 346–352 (2008).
   PubMed Web of Science ®Google Scholar
• Kawamoto K, Enokida H, Gotanda T et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem. Biophys. Res. Commun.339(3), 790–796 (2006).
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Karagas MR, Andrew A et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res.65(16), 7081–7085 (2005).
   PubMed Web of Science ®Google Scholar
• Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res.72, 141–196 (1998).
   PubMed Web of Science ®Google Scholar
• Laird PW, Jackson-Grusby L, Fazeli A et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell81(2), 197–205 (1995).
   PubMed Web of Science ®Google Scholar
• Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol.249, 135–164 (2000).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol.20(10), 2429–2440 (2002).
   PubMed Web of Science ®Google Scholar
• Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol.18(5), 956–962 (2000).
   PubMed Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Giles FJ et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2´-deoxycytidine (decitabine) in hematopoietic malignancies. Blood103(5), 1635–1640 (2004).
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer1(3), 194–202 (2001).
   PubMed Web of Science ®Google Scholar
• Richon VM, O’Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res.8(3), 662–664 (2002).
   PubMed Web of Science ®Google Scholar